Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...